Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label comparison of HJ178 capsules versus empagliflozin in type 2 diabetes inadequately controlled after DPP-4 inhibitor therapy
CTR20252174Phase 2Active
- Sponsor
- Huajian Future
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HJ178 in type 2 diabetes mellitus (T2DM), sponsored by Huajian Future. Started Jun 2025; status: active.
02
Drugs
HJ178
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20252174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252174.